222 results about "Obesity prevention" patented technology

A device for controlling the expansion of a hollow internal organ, comprising an inflatable balloon, which is inserted in an uninflated state into the desired position close to the organ using minimally invasive procedures. After insertion, the balloon is inflated to its required size and shape. The invention is useful for restricting the expansion of the stomach during meals, thus inducing a feeling of satiety and preventing over-eating. Inflation may be performed through a catheter connected to a readily accessible inflation port. In the case of the gastric embodiment, the balloon may be positioned pro-peritoneally, such that the procedure is surgically simple. One or more sensors located close to the organ to be controlled, may monitor a physiological effect relating to the organ, and the output of the sensor used to control the level of inflation of the balloon in order to correct the condition being monitored.

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and / or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α,25-dihydroxyvitamin D2 or a pharmaceutical composition that includes such an analog to a subject in need thereof. The analog may be a 19-nor vitamin D analog such as a compound of formula IA, a compound of formula IB, or a mixture thereof where the variables R1, R2, and R3 have the values described herein.

The present invention is directed to methods and agents for modulating the differentiation potential and / or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.

A class of acyl sulfamides comprises compounds that are potent ligands for PPAR gamma and generally have antagonist or partial agonist activity. The compounds may be useful in the treatment, control or prevention of obesity, non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, inflammation, and other PPAR gamma mediated diseases, disorders and conditions.

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

A nutritional composition for controlling blood sugar level comprising a protein, a lipid and a carbohydrate, wherein energy percentages supplied by the protein, lipid and carbohydrate are 10 to 25%, 20 to 35% and 40 to 60%, respectively; and oleic acid in the lipid energy percentage is 60 to 90% and palatinose and / or trehalulose in the carbohydrate energy percentage is 60 to 100%. The composition is useful as an oral or tube feeding nutrient for nutritional management or blood sugar level control of patients suffering from diabetes and glucose intolerance, or for obesity prevention, a therapeutic diet, a diet for diabetic patients at home, an obesity preventive diet or a food with health claims.

The invention discloses a glucagon like peptide(GLP)-1 mutant polypeptide and a preparation method, a medicinal composition and use thereof. The mutant polypeptide is formed by bonding a Cys-containing elongation peptide to the N terminal of the glucagon like peptide-1 mutant, the mutant polypeptide itself folds to form a disulfide bond. The glucagon like peptide-1 mutant polypeptide is used for preparing a medicinal composition for treating diabetes and treating and preventing obesity. For overcoming the drawbacks of short retention time in body and need of daily injection administration of clinic GLP-1 analogue, the invention provides the GLP-1 analogue which has a longer half-life period. With the longer half-life period, the GLP-1 mutant polypeptide is not required to be injected into a patient every day, and can increase the obedience of the patient effectively.

There are provided foods and beverages that will suppress the absorption of dietary lipids, thereby suppressing the rise of triglyceride in blood. High-molecular weight polyphenol fractions recovered from oolong tea are added to foods or beverages as an active ingredient for inhibiting lipase activity. The foods and beverages of the present invention are safe and their inherent flavor has not been impaired; hence, they may be taken in routinely so that the lipase inhibitory action of the high-molecular weight polyphenol fractions will suppress the rise of triglyceride in blood and prevent obesity.

The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.

The invention provides EXENDIN-4 analogue dimer and a preparation method and application thereof. The dimer is prepared from two same or different EXENDIN-4 analogues by forming a disulfide bond between the monomers through cysteine. The preparation method of the EXENDIN-4 analogue dimer comprises the steps of synthesizing an EXENDIN-4 analogue monomer by an Fmoc solid-phase polypeptide synthesis method, and forming the dimer from the monomer. The invention also provides an application of the EXENDIN-4 analogue dimer in preparing a medicine for treating diabetes mellitus and treating and / or preventing obesity or obesity-related diseases. The in-vivo half-life period of the EXENDIN-4 analogue dimer formed from the monomer provided by the invention can exceed 14-96 hours, which is obviously prolonged as compared with the half-life period (only 2.4 hours) of EXENDIN-4 in separate administration, thereby greatly facilitating the clinical popularization and application.

The invention discloses a medicinal composition for treating or preventing the obesity and metabolic syndromes, and belongs to the medicine field. The medicinal composition treats orlistat and acarbose as medicinal active components, so the application amount of orlistat in the medicinal composition is substantially reduced, thereby the risk of the damage of orlistat to the liver of a body is reduced. The medicinal composition has a substantial synergistic effect when the medicinal composition is used for treating or preventing the obesity and the metabolic syndromes, can reduces the diabetes and angiocardiopathy suffering risks of obese patients, and has a wide medical application prospect.

The present invention relates to compositions comprising PYY, PYY3-36, or a PYY agonist, and an anti-obesity agent, useful for the treatment and prevention of obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.

A combination chair and leg extension apparatus is provided. The apparatus uses a pneumatic source of resistence to provide a stowable flexor for the leg muscles which remains connected to the chair. Variations of the combination also provide for a combination desk, chair and leg extension apparatus, and a combination office chair and leg extension apparatus. The invention is to assist in prevention of obesity, particularly in children.

Disclosed are botanical compositions, and more particularly to compositions having particularly beneficial therapeutic or prophylactic properties in a mammal. In particular, the compositions of the present inventions are useful inter alia in the treatment and / or prophylaxis of obesity, overeating, and other eating disorders, as well as an oral supplement in place of, or commensurate with, the consumption of food. The compositions of the present invention may be conveniently formulated for suitable administration, such as, for example, as a dried composition. In particularly preferred embodiments, the compositions of the present invention encompass formulations that comprise, consist essentially of, or consist of, a plurality of at least three herbal plants, horticultural and / or botanical equivalents, and / or extracts thereof, having similar or equivalent medicinal or therapeutic properties.

The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic and alpha-linolenic acid.

A nasal device (10-16) for obesity prevention and treatment and its method of use are disclosed. The device comprises a check valve (20, 20′) and a cylindrical or conical airtight tube (30, 32′, 33, 34, 34′ / 36′) with an opening at each end. The valve is so fastened or connected to the tube at one end as to form a one-way air channel / passage. The tube conforms to or fits the interiors of different nostrils air-tightly in a variety of ways (32′, 34, 38, 40, 34′, 40′, 46). A pair of such devices can be connected with a flexible strip (42) or a band (44). Inserting the device into the nostril, a wearer can inhale through the nose but has to exhale through the mouth. This reduces the wearer's appetite for food and slows down eating. The wearer can easily remove the device after eating or whenever desired.

This invention relates to novel heterocyclic compounds, compositions, and methods for treating or preventing obesity and obesity-related diseases.

The invention discloses bifidobacterium animalis NX-6 and application thereof in preparation of lipid-lowering and weight-losing medicines, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis NX-6 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 20114. The uninactivated and inactivated fermentation supernate, bacterial suspension and cell disrupted supernate of novel bifidobacterium animalis NX-6 show good effects of slowing down weight and body length increase, improving body mass index(BMI) and reducing fat area percentage on zebrafish, and have a potential weight losing effect; triglyceride (TG) and total cholesterol (TC) in a zebrafish hyperlipidemia model body can be obviously reduced, and a good hypolipidemic effect is shown. The novel bifidobacterium animalis NX-6 disclosed by the invention has a huge potential application prospect in the aspect of preparing medicines fortreating and / or preventing obesity and hyperlipidemia.

A combination chair and leg extension apparatus is provided. The apparatus uses a pneumatic source of resistence to provide a stowable flexor for the leg muscles which remains connected to the chair. Variations of the combination also provide for a combination desk, chair and leg extension apparatus, and a combination office chair and leg extension apparatus. The invention is to assist in prevention of obesity, particularly in children.

Use of at least one strain of a microorganism and / or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and / or a metabolite thereof may be administered to the subject for the treatment and / or prevention of excess weight and / or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and / or a metabolite thereof is administered to the subject for the treatment and / or prevention of obesity and / or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and / or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and / or B. lactis.

The invention relates to the use of specifically designed lipid component with a mixture of milk fat and vegetable fat and present as lipid globules with a large size, for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.

The invention relates to methods of treating or preventing obesity, type 2 diabetes, metabolic syndrome, or glucose intolerance using pyrido[3,2-e]pyrazines which are inhibitors of PDE10. The invention further relates to methods of reducing body fat or body weight.

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

The present invention relates generally to a new cluster of correlating molecules in a tissue or at least one cell of a tissue for instance a cell of a blood tissue, preferably such myeloid cells and of identifying the condition of the genes expression said correlating molecules or of the expression levels of said molecules in a method or system for identifying obesity and the risk at obesity-related metabolic diseases such as the obesity associated cardiovascular risk or obesity-related insulin resistance. This system of method provides information on how to modulate the correlating molecules to treat or prevent obesity and to prevent the obesity-related metabolic diseases.

The invention discloses a pure natural sweet potato beverage in original color and taste, which belongs to the field of food production process. The beverage is made from purple sweet potatoes as raw material, the process includes enzymolyzing purple sweet potato residue, preserving nutrients and color, flavoring, executing non-thermal sterilization treatment with a rare earth ultrasonic transducer, and packaging. According to the invention, the natural purple potato and the baking purple potato are used for providing natural flavor of the beverage, amylases and pectase are used to digest starch to provide a part of the sweet taste, and a large amount of nutrients such as antioxidants, multiple amino-acids or the like are preserved by maximum in the whole treatment process. The sweet red wine has bright color, fragrance special for purple sweet potato, slightly sweet taste, pure mouth feeling, long aftertaste, without sediment or cloudiness, which is suitable for long-term storage, and convenient for taking. The wine has functions of blood circulation promotion, fatigue recovering, obesity prevention and treatment, gastrointestinal function improvement, skin moistening or the like, is capable of suppressing generation of lipid peroxide, preventing human body aging, and has relative great cancer prevention effect.

The invention relates to the field of processing of dairy products, and specifically relates to low-fat cheddar cheese containing lactobacillus casei generating exopolysaccharides and a preparation method of the low-fat cheddar cheese. Under the condition that any fat substituents and glue additives are not added, the defect that character and fusing property of low-fat cheddar cheese are poor due to lipopenia is improved by means of natural exopolysaccharide generating bacteria, and the low-fat cheddar cheese approaches whole fat cheddar cheese. The fat content of the low-fat cheddar cheese provided by the invention is reduced by over 50% compared with a normal whole fat group. The cheese prepared by the invention is not only low in fat content, but also is easy to accept by consumers in character and taste. The product is suitable for crowds and children with obesity and diabetes to eat. In addition, the cheese is beneficial for preventing diseases such as obesity and cardia-cerebrovascular diseases for common crowds.

A nutritive composite vitamine-trace element-white sugar necessary for normal energy metabolism for preventing and treating obesity, fatty liver, alcoholic liver, diabetes and hyperlipemia is prepared from VB1, VB2, VC, Se, Zn and white sugar. It can be used as food or food additive.

The invention relates to a health-care food containing natural fucoxanthin, which is a soft capsule. Moreover, an obesity preventing model method is adopted, and the fucoxanthin is used as a functional factor for carrying out a fat reducing experiment on a rat. By the display of data analysis, the weight and the perinephric spermary fat weight of the rat fed with the fucoxanthin are obviously lowered in comparison with those of a model set. Furthermore, the fat cell area is obviously reduced in comparison with that of the model set and a blank set. The result shows that the fucoxanthin has a very good fat reducing effect, and a favorable basis is provided to the application of substances containing the fucoxanthin in the field of health-care foods.